Table 1 Demographic and clinical characteristics of study cohort.

From: MLIP genotype as a predictor of pharmacological response in primary open-angle glaucoma and ocular hypertension

 

Total (N)

R (n)

NR (n)

p

BL

72

44

28

 

Age, years (M ± SD)

50.0 ± 15.3

58.2 ± 14.3

52.5 ± 16.5

0.126

Female (%)

39 (54.1%)

26 (59.1%)

13 (46.4%)

0.293

Male (%)

33 (45.9%)

18 (40.9%)

15 (53.6%)

 

IOP1, mmHg (M ± SD)

24.3 ± 2.9

24.8 ± 3.2

23.4 ± 2.1

0.063

IOP2, mmHg (M ± SD)

19.0 ± 3.1

17.2 ± 2.3

21.6 ± 2.4

0.0001

BCVA (M ± SD)

0.88 ± 0.25

0.92 ± 0.24

0.83 ± 0.26

0.161

PG

80

45

35

 

Age, years (M ± SD)

57.8 ± 13.4

57.6 ± 13.6

57.9 ± 13.4

0.914

Female (%)

43 (54%)

23 (51%)

20 (57%)

0.447

Male (%)

37 (46%)

22 (49%)

15 (43%)

 

IOP1, mmHg (M ± SD)

24.4 ± 2.2

24.6 ± 3.7

24.3 ± 3.1

0.701

IOP2, mmHg (M ± SD)

18.9 ± 3.3

16.8 ± 2.5

21.3 ± 3.1

0.0001

BCVA (M ± SD)

0.90 ± 0.29

0.99 ± 0.21

0.80 ± 0.34

0.006

  1. BL, beta-blocker (timolol maleate) treatment group; PG, prostaglandin analogue (latanoprost) treatment group; R, responder individuals; NR, non-responder individuals; (N)(n), number of individuals; IOP1, intraocular pressure before treatment; IOP2, after treatment; BCVA, best corrected visual acuity (decimal); M ± SD, mean ± standard deviation; p, p-value for responders vs non-responders.